Better integration before more automation
The first product hypothesis is deliberately narrow: a research-to-clinic MVP for GAD assessment and treatment-pathway stratification, initially used under clinician supervision in selected research or GGZ settings.
Structured clinical and cognitive assessment
Exploratory multimodal profiling
Clinician-facing visualisation of patterns and uncertainty
Longitudinal clinical and cognitive monitoring
Research support for treatment-response
hypotheses
What the first version will not do
It will not diagnose GAD or another condition.
It will not autonomously prescribe or select treatment.
It will not replace a qualified clinician.
It will not claim validated predictive accuracy before independent testing.
It will not require QEEG if that modality fails to add meaningful value.
Implementation intent
Principle
Show evidence, uncertainty and override options rather than automated conclusions.
Clinician in the loop
Compare simple clinical models with increasingly complex multimodal models.
Progressive evidence
Minimise data, separate identities and use controlled, auditable access.
Privacy by design
Measure assessment time, usability and integration burden in real practice.
Workflow fit
Define intended purpose early and review MDR and EU AI Act implications.
Regulatory awareness
Explore a validation partnership
If your organisation works in anxiety care, neuropsychology, cognitive rehabilitation, QEEG or responsible medical software, we would welcome an introductory conversation
